SOUTH SAN FRANCISCO, Calif.--(EON: Enhanced Online News)--CytomX Therapeutics, the Probody™ therapeutics company, today announced that the Company’s Chief Executive Officer, Sean McCarthy, D. Phil., will present at the 12th Annual BIO Investor Forum on Tuesday, Oct. 8, 2013, at 9 a.m. PDT. Dr. McCarthy will provide a company overview and discuss recent progress with CytomX’s Probody Platform and therapeutic programs.
Hosted by the Biotechnology Industry Organization (BIO), the 12th Annual BIO Investor Forum features leading private and emerging public companies. The meeting will take place Oct. 8-9, 2013, at the Palace Hotel in San Francisco.
CytomX Therapeutics, the Probody™ therapeutics company, is dedicated to transforming lives with safer, more effective therapies. CytomX’s Probody Platform represents a disruptive approach to discovering and developing the next generation of antibody therapeutics and is enabling the development of a diversified pipeline in major unmet medical needs including cancer and inflammation. Probodies are masked antibodies that remain inert in healthy tissue but are activated specifically in the disease microenvironment. This breakthrough selectivity allows CytomX to drug previously undruggable antibody targets, unlock new therapeutic targets for antibody-drug conjugates (ADCs), and focus activity in the tumor microenvironment, thereby redefining the landscape for therapeutic antibodies. CytomX is led by a seasoned and proven management team and is financed by leading life science investors including Third Rock Ventures, Canaan Partners and the Roche Venture Fund. For more information, please visit www.cytomx.com.